Treatment of Subarachnoid Hemorrhage With Human Albumin

Subarachnoid Hemorrhage Clinical Trial

— ALISAH  

Official title:

Treatment of Subarachnoid Hemorrhage With Human Albumin

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01747408
• Other study ID #: H-21012
• Status: Terminated
• Phase: Phase 1
• First received: June 23, 2011
• Last updated: December 10, 2012
• Start date: June 2006
• Est. completion date: May 2011

Study information

• Verified date: December 2012
• Source: Baylor College of Medicine
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The proposed study was set up to evaluate the tolerability and safety of 25% human albumin (HA) therapy in patients with subarachnoid hemorrhage (SAH). It is estimated that 37,500 people in the USA have SAH every year. SAH is associated with a 51% mortality rate and one third of survivors are left functionally dependent. Cerebral vasospasm (CV) has been identified as the most important reason for neurological deterioration. CV may be due to multiple molecular mechanisms. The use of a neuroprotective agent with various actions, likes HA, would be important for prevention of CV and improved clinical outcome in patients with SAH. The proposed open-label, dose-escalation study will have important public health implications by providing necessary information for a definitive phase III clinical trial regarding the efficacy of treatment with HA in patients with SAH. The study was to enroll a maximum of 80 patients with SAH who meet the eligibility criteria. Four dosages of HA (0.625, 1.25, 1.875, and 2.5 g/kg) administered daily for seven days will be evaluated. The lowest dosage was to be evaluated in the first group of 20 subjects. A specific safety threshold was defined based on data from previous studies. The Data and Safety Monitoring Board approved or disapproved advancing to the next higher HA dosage based on the evaluation of the rate of congestive heart failure (CHF). The study assessed three outcomes: safety and tolerability of the HA dosages and the functional outcome. The primary tolerability outcome was defined as the subject's ability to receive the full allocated dose of HA without incurring frank CHF that requires termination of treatment. Secondary safety outcomes were serious adverse events (including neurological and medical complications, and anaphylactic reactions). Neurological complications comprise incidence of CV, rebleeding, hydrocephalus, and seizures after treatment. The three-month functional outcome determined, by Glasgow Outcome Scale, Barthel Index, modified Rankin Scale, NIH Stroke Scale and Stroke Impact Scale was measured to obtain a preliminary estimate of the treatment effect of HA. The timeline of the study is three years.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 47
• Est. completion date: May 2011
• Est. primary completion date: July 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients (male or female) must be at least 18 but younger than 80 years of age.

• Onset of new neurological signs of subarachnoid hemorrhage within 72 hours at the time of evaluation and initiation of treatment with 25% human albumin.

• Clinical signs consistent with the diagnosis of subarachnoid hemorrhage including severe thunderclap headache, cranial nerve abnormalities, decreased level of consciousness, meningismus and focal neurological deficits.

• Head computed tomography demonstrates subarachnoid hemorrhage (rating scale 2-4).

• Cerebral angiography reveals the presence of saccular aneurysm(s) in a location that explains the subarachnoid hemorrhage.

• Treatment of cerebral aneurysm must be carried out prior to treatment initiation but within 72 hours of symptom onset. Accepted treatments of aneurysms include surgical clipping or endovascular embolization.

• Signed and dated informed written consent by the subject or his/her legally authorized representative.

Exclusion Criteria:

• Time of symptom onset cannot be reliably assessed.

• No demonstrable aneurysm by cerebral angiography.

• Evidence of traumatic, mycotic, or fusiform aneurysm by cerebral angiography.

• World Federation of Neurological Surgeons scale of IV and V

• Head computed tomography rating scale of 0 - 1

• History within the past 6 months, and/or physical findings on admission of decompensated heart failure (NYHA Class III and IV or heart failure requiring hospitalization).

• Patient has received albumin prior to treatment assignment during the present admission.

• Hospitalization for or diagnosis of acute myocardial infarction within the preceding 3 months.

• Symptoms or electrocardiographic signs indicative of acute myocardial infarction on admission.

• Electrocardiographic evidence and/or physical findings compatible with second- or third-degree heart block, or of cardiac arrhythmia associated with hemodynamic instability.

• Echocardiogram performed before treatment revealing a left ventricular ejection fraction > or = 40% (if available).

• Serum creatinine > 2.0 mg/dl or creatinine clearance < 50 ml/min.

• Pregnancy, lactation or parturition within previous 30 days.

• Known allergy to albumin.

• Severe prior physical disability (Rankin Scale > 2) that precludes evaluation of clinical outcome measures.

• History of severe chronic obstructive lung disease (FEV1 < 50% predicted, increased shortness of breath, and repeated exacerbations which have an impact on patients' quality of life).

• History of confirmed or suspected liver failure (increased prothrombin time, elevated liver enzymes, hypoalbuminemia, and hyperbilirrubinemia with or without peripheral edema and encephalopathy)

• Current participation in another drug treatment protocol.

• Severe terminal disease with life expectancy less than 6 months.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hemorrhage
• Subarachnoid Hemorrhage

Intervention

Drug:
• Human Albumin
25% human albumin given in four escalating doses: Group 1: .625g/kg infused over 3hrs daily X 7day Group 2: 1.25g/kg infused over 3hrs daily X 7day Group 3: 1.875g/kg infused over 3hrs daily X 7day Group 4: 2.5g/kg infused over 3hrs daily X 7day

Locations

Country	Name	City	State
United States	Baylor College of Medicine	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Baylor College of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participatns with cardiovascular adverse events as a measure of safety and tolerability	The study will investigate the number of patients experiencing moderate-to-severe acute heart failure for any given dosage tier directly related to treatment administration. Specifically, if at least 2 patients per dosage tier experience such serious event the study will be terminated.	Up to 48 hours after treatment administration	Yes
Secondary	GOS	The study will measure the the Glasgow Outcome Scale to obtain preliminary estimates of treatment effects.	3 months after enrollment	No
Secondary	mRs	The study will measure the the modified Rankin Scale to obtain preliminary estimates of treatment effects.	3 months after study enrollment	No
Secondary	NIHSS	The study will measure the NIH Stroke Scale to obtain preliminary estimates of treatment effects.	3 months after enrollment	No
Secondary	SIS	The study will measure the Stroke Impact Scale to obtain preliminary estimates of treatment effects.	3 months after enrollment	No